OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Paolo Marzullo, T. Daffara, Chiara Mele, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 8, pp. 1587-1598
Open Access | Times Cited: 21
Paolo Marzullo, T. Daffara, Chiara Mele, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 8, pp. 1587-1598
Open Access | Times Cited: 21
Showing 21 citing articles:
Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 25
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 25
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 6
Dimitrios Patoulias, Theocharis Koufakis, Ieva Ruža, et al.
Pragmatic and Observational Research (2024) Vol. Volume 15, pp. 139-149
Open Access | Times Cited: 6
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
Cesare Berra, Maria Chiara Rossi, Marco Mirani, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 16
Cesare Berra, Maria Chiara Rossi, Marco Mirani, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 16
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes
Caroline Swift, Monica Frazer, Andrew Sargent, et al.
Clinical Therapeutics (2025)
Open Access
Caroline Swift, Monica Frazer, Andrew Sargent, et al.
Clinical Therapeutics (2025)
Open Access
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study
Virginia Bellido, Cristina Abreu Padín, Andrei‐Mircea Catarig, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4938-4938
Open Access | Times Cited: 17
Virginia Bellido, Cristina Abreu Padín, Andrei‐Mircea Catarig, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4938-4938
Open Access | Times Cited: 17
The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study
Sara Alenzi, Abdullah Alzahrani, Afnan Aljaloud, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Sara Alenzi, Abdullah Alzahrani, Afnan Aljaloud, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
Zhen Ruan, Yixuan Jiang, Honghao Shi, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 161-176
Closed Access | Times Cited: 7
Zhen Ruan, Yixuan Jiang, Honghao Shi, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 161-176
Closed Access | Times Cited: 7
Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD )
Óscar Moreno, Rebeca Reyes‐García, Inés Modrego Pardo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 4, pp. 1519-1523
Open Access | Times Cited: 7
Óscar Moreno, Rebeca Reyes‐García, Inés Modrego Pardo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 4, pp. 1519-1523
Open Access | Times Cited: 7
Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study
Hodaka Yamada, Masashi Yoshida, Daisuke Suzuki, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 10, pp. 1779-1788
Open Access | Times Cited: 9
Hodaka Yamada, Masashi Yoshida, Daisuke Suzuki, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 10, pp. 1779-1788
Open Access | Times Cited: 9
Tendências atuais na eficácia e segurança da Semaglutida no controle glicêmico de pacientes diabéticos: Revisão de literatura
Alyne Werner Mota Pereira, Júlia Andrade Pereira, S. Ferreira
Research Society and Development (2024) Vol. 13, Iss. 7, pp. e11013746426-e11013746426
Open Access | Times Cited: 1
Alyne Werner Mota Pereira, Júlia Andrade Pereira, S. Ferreira
Research Society and Development (2024) Vol. 13, Iss. 7, pp. e11013746426-e11013746426
Open Access | Times Cited: 1
Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Doulatram‐Gamgaram, et al.
Nutrients (2024) Vol. 16, Iss. 15, pp. 2545-2545
Open Access | Times Cited: 1
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Doulatram‐Gamgaram, et al.
Nutrients (2024) Vol. 16, Iss. 15, pp. 2545-2545
Open Access | Times Cited: 1
Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
Carlos Mario Balcázar Valencia, Andrés Felipe García Ramos, Luis Miguel Osorio-Toro, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1667-1673
Open Access | Times Cited: 1
Carlos Mario Balcázar Valencia, Andrés Felipe García Ramos, Luis Miguel Osorio-Toro, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1667-1673
Open Access | Times Cited: 1
Real-World Use of Once-Weekly Semaglutide in Thai Patients with Type 2 Diabetes Mellitus in a Private Hospital Setting
Yotsapon Thewjitcharoen, Nalin Yenseung, Siriwan Butadej, et al.
Journal of the ASEAN Federation of Endocrine Societies (2023) Vol. 38, Iss. 1, pp. 21-28
Open Access | Times Cited: 3
Yotsapon Thewjitcharoen, Nalin Yenseung, Siriwan Butadej, et al.
Journal of the ASEAN Federation of Endocrine Societies (2023) Vol. 38, Iss. 1, pp. 21-28
Open Access | Times Cited: 3
Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes
Monica Frazer, Caroline Swift, Andrew Sargent, et al.
Journal of Diabetes & Metabolic Disorders (2023) Vol. 23, Iss. 1, pp. 727-737
Open Access | Times Cited: 3
Monica Frazer, Caroline Swift, Andrew Sargent, et al.
Journal of Diabetes & Metabolic Disorders (2023) Vol. 23, Iss. 1, pp. 727-737
Open Access | Times Cited: 3
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
Tatjana Milenkovikj, Biljana Chekorova Mitreva, Sasha Jovanovska Mishevska, et al.
Diabetes Research and Clinical Practice (2023) Vol. 206, pp. 111018-111018
Open Access | Times Cited: 1
Tatjana Milenkovikj, Biljana Chekorova Mitreva, Sasha Jovanovska Mishevska, et al.
Diabetes Research and Clinical Practice (2023) Vol. 206, pp. 111018-111018
Open Access | Times Cited: 1
factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme
Tom Crabtree, Karen Adamson, Alex Bickerton, et al.
British Journal of Diabetes (2023) Vol. 23, Iss. 2, pp. 94-100
Open Access
Tom Crabtree, Karen Adamson, Alex Bickerton, et al.
British Journal of Diabetes (2023) Vol. 23, Iss. 2, pp. 94-100
Open Access
Semaglutide in routine clinical practice: interesting news from real-world evidence
Gloria Formoso, Marco Giorgio Baroni
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 8, pp. 1599-1600
Closed Access
Gloria Formoso, Marco Giorgio Baroni
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 8, pp. 1599-1600
Closed Access
